Last updated: September 2, 2026
Fexofenadine hydrochloride and pseudoephedrine hydrochloride are mature over-the-counter allergy and nasal-congestion ingredients. Their principal branded combination in the United States is Allegra-D, marketed by Sanofi’s consumer-health business, Opella. The product has no meaningful patent-based exclusivity barrier, faces established generic competition, and generates value through brand recognition, seasonal demand, retail distribution, and pricing rather than exclusivity.
The financial outlook is stable but low-growth. Fexofenadine supports a broad, recurring allergy market. Pseudoephedrine increases the combination product’s clinical utility but limits distribution because of federal purchase controls, identification requirements, transaction logging, and state-level restrictions. Product-level revenue is not separately disclosed by Sanofi, so the financial trajectory must be assessed through category structure, brand strategy, regulatory controls, and competitive pricing.
What products contain fexofenadine hydrochloride and pseudoephedrine hydrochloride?
The principal U.S. combination products contain fexofenadine hydrochloride, a second-generation antihistamine, and pseudoephedrine hydrochloride, an oral nasal decongestant.
| Product type |
Typical strength |
Primary use |
U.S. commercial status |
| Allegra-D 12 Hour |
Fexofenadine HCl 60 mg / pseudoephedrine HCl 120 mg |
Allergy symptoms with nasal congestion |
OTC, behind the pharmacy counter |
| Allegra-D 24 Hour |
Fexofenadine HCl 180 mg / pseudoephedrine HCl 240 mg |
Once-daily allergy symptoms with congestion |
OTC, behind the pharmacy counter |
| Fexofenadine-only products |
30, 60, 180 mg |
Allergic rhinitis and urticaria |
OTC generic and branded |
| Pseudoephedrine-only products |
Multiple immediate- and extended-release strengths |
Nasal congestion |
OTC, behind the pharmacy counter |
Fexofenadine is marketed independently under Allegra and numerous generic labels. The combination product competes with loratadine/pseudoephedrine, sold as Claritin-D and generic equivalents, and cetirizine/pseudoephedrine, sold as Zyrtec-D and generic equivalents.
What is the FDA regulatory status of Allegra-D?
Allegra-D is an FDA-approved nonprescription combination product. The active ingredients are regulated through the FDA’s over-the-counter monograph and new-drug-application framework for antihistamines and oral nasal decongestants. The product is sold without a prescription but is not placed on open retail shelves because pseudoephedrine is subject to federal controls.[1][2]
Fexofenadine received U.S. prescription approval before conversion to nonprescription status. The FDA approved Allegra for prescription use in the 1990s and later allowed over-the-counter marketing of fexofenadine products. The switch expanded the addressable market while increasing substitution from branded Allegra to store-brand and generic products.
Pseudoephedrine remains legally available without a prescription in the United States, but federal law requires retail controls. The Combat Methamphetamine Epidemic Act limits daily and monthly purchases, requires purchaser identification and transaction records, and requires products to be stored behind the counter or in a secured area.[3]
What is the Orange Book status of fexofenadine-pseudoephedrine products?
Fexofenadine-pseudoephedrine products do not have a current patent-driven exclusivity position comparable to a recently launched prescription drug. The original innovator patents and regulatory exclusivities for fexofenadine-based products have expired, allowing generic competition.
The Orange Book remains relevant for product identification, NDA listings, therapeutic equivalence, and any residual listed patents or exclusivities. It is not, however, the primary commercial determinant for this category. The principal barriers are retail access, consumer brand preference, manufacturing scale, and control of pseudoephedrine distribution.[4]
What patents protect Allegra-D?
The original patent estate around fexofenadine and its pharmaceutical use is mature. Patent protection for the active ingredient and core therapeutic applications has expired. The combination product also has no commercially significant period of market exclusivity remaining.
Potential intellectual-property protection can still arise from:
- Extended-release tablet design.
- Inactive-ingredient composition.
- Manufacturing processes.
- Packaging and labeling.
- Specific dosage regimens.
- Trademark rights associated with Allegra and Allegra-D.
These rights do not generally prevent generic entry into the active-ingredient combination. A generic manufacturer can compete by filing or maintaining an abbreviated application, relying on monograph compliance, or marketing an equivalent OTC product where permitted.
When did fexofenadine lose exclusivity?
Fexofenadine lost practical exclusivity years ago. The molecule is now widely available as a generic antihistamine and is sold by multiple manufacturers in the United States and international markets.
The commercial sequence was:
| Period |
Event |
Market effect |
| 1990s |
Prescription fexofenadine launched |
Premium branded antihistamine positioning |
| Late 1990s to early 2000s |
OTC transition |
Larger consumer market and retail expansion |
| 2010s |
Generic fexofenadine became broadly available |
Branded price and share pressure |
| Current market |
Mature OTC category |
Competition based on price, distribution, and brand |
The absence of active core exclusivity means that branded Allegra-D cannot rely on patent-based price protection. Its remaining advantages are consumer awareness, perceived efficacy, pharmacy-channel presence, and the ability to offer a recognized combination of a nonsedating antihistamine with pseudoephedrine.
How strong is the patent estate for fexofenadine and pseudoephedrine?
The patent estate is weak as a barrier to market entry and moderate as a defensive tool around formulations and brands.
| Protection category |
Current strength |
Commercial significance |
| Fexofenadine active ingredient |
Low |
Core composition is long off-patent |
| Pseudoephedrine active ingredient |
Low |
Long-established generic ingredient |
| Fexofenadine-pseudoephedrine combination |
Low to moderate |
Formulation differences may remain, but do not block broad substitution |
| Extended-release technology |
Moderate in selected products |
Can affect product design and regulatory filings |
| Manufacturing know-how |
Moderate |
Supports quality, yield, and supply reliability |
| Allegra and Allegra-D trademarks |
Strong for brand identity |
Protects branding, not active ingredients |
| OTC labeling and regulatory compliance |
Moderate |
Creates operational requirements for competitors |
Manufacturing know-how has more practical value than composition patents. Extended-release products require controlled dissolution profiles, stable tablet performance, and consistent pseudoephedrine release. Those requirements can create technical and regulatory friction, but they are not equivalent to patent exclusivity.
Which companies compete with Allegra-D?
The competitive market includes branded products, store brands, pharmacy-counter generics, and single-ingredient substitutes.
| Competitor |
Active ingredients |
Competitive position |
| Allegra-D |
Fexofenadine / pseudoephedrine |
Recognized brand with non-sedating antihistamine positioning |
| Claritin-D |
Loratadine / pseudoephedrine |
Major branded alternative |
| Zyrtec-D |
Cetirizine / pseudoephedrine |
Strong allergy brand; some consumers perceive greater sedation risk |
| Generic fexofenadine-pseudoephedrine |
Same active ingredients |
Main price competitor |
| Fexofenadine alone |
Fexofenadine |
Substitute when congestion is limited |
| Loratadine or cetirizine alone |
Alternative antihistamines |
Compete for allergy treatment occasions |
| Phenylephrine products |
Antihistamine or decongestant combinations |
Retail substitute, although regulatory prospects are weaker |
Fexofenadine’s nonsedating positioning supports premium demand relative to older antihistamines. The combination’s main weakness is that pseudoephedrine access requires a pharmacy transaction, while fexofenadine-only products can be purchased directly from retail shelves or online channels where permitted.
What market dynamics affect fexofenadine-pseudoephedrine sales?
Allergy prevalence and seasonality
Demand is seasonal, with volume typically increasing during spring and early summer allergy periods. Weather, pollen counts, respiratory illness patterns, and regional climate conditions affect sell-through. The allergy market also has a recurring baseline because allergic rhinitis and chronic urticaria require repeated treatment.
Fexofenadine-only products benefit from both seasonal allergy demand and year-round urticaria treatment. Allegra-D has a narrower demand profile because pseudoephedrine is most valuable when congestion is prominent.
Generic substitution
Generic substitution places the strongest pressure on branded revenue. Consumers can purchase fexofenadine at substantially lower prices, and retailers use private-label products to improve margin or reduce consumer cost.
The combination product has somewhat greater brand defensibility because:
- It requires pharmacy-counter access.
- Consumers may prefer a known dosage combination.
- Extended-release performance is important.
- The retail purchase is often symptom-driven and time-sensitive.
These factors support brand retention but do not prevent price competition.
Pseudoephedrine controls
Federal restrictions reduce impulse purchases and complicate e-commerce fulfillment. Retailers must manage inventory, compliance systems, customer identification, and purchase limits. These controls increase the operating burden for manufacturers and retailers and reduce the convenience advantage of Allegra-D compared with shelf-available antihistamines.
State laws can impose stricter controls, including prescription requirements or additional transaction restrictions. Geographic variation creates compliance and distribution complexity.
Oral phenylephrine pressure
The FDA proposed removing oral phenylephrine from the OTC monograph after determining that available data did not support its effectiveness as a nasal decongestant at the permitted oral dose.[5] If finalized, that action could shift some consumers and retailers toward pseudoephedrine products, including Allegra-D. It could also reduce the number of effective oral decongestant combinations available in open retail channels.
The impact would depend on final FDA action, retailer assortment decisions, and consumer willingness to complete a pharmacy-counter purchase.
What is the financial trajectory for Allegra-D and its ingredients?
The financial profile is that of a mature consumer-health franchise rather than a growth-stage pharmaceutical asset.
| Financial driver |
Direction |
Impact |
| Unit volume |
Flat to modestly growing |
Supported by recurring allergy demand |
| Branded pricing |
Positive but limited |
Inflation and premium positioning provide some support |
| Generic pricing |
Downward |
Private-label competition compresses category revenue |
| Product mix |
Mixed |
24-hour products can support value per treatment day |
| Seasonal demand |
Volatile |
Creates quarterly and annual sales variability |
| Distribution cost |
Higher for pseudoephedrine products |
Pharmacy-counter compliance and inventory controls |
| Marketing return |
Selective |
Brand awareness matters, but mature categories limit incremental gains |
| Gross margin |
Generally attractive |
OTC products have low clinical-development costs |
| Regulatory risk |
Moderate |
Pseudoephedrine restrictions and decongestant policy changes affect access |
Sanofi reports consumer-health performance at a business-segment level rather than disclosing separate sales for Allegra-D, Allegra, or each formulation.[6] As a result, the product’s revenue and operating profit cannot be isolated from public company reporting.
The likely financial trajectory is:
- Revenue remains resilient during allergy seasons.
- Volume growth is limited by generic substitution.
- Branded sales depend on pricing, merchandising, and advertising.
- Fexofenadine-only products offer a larger and more stable consumer base than the pseudoephedrine combination.
- Allegra-D retains value as a high-utility product for consumers needing both allergy control and congestion relief.
- Long-term growth is more likely to come from portfolio management and geographic expansion than from new medical indications.
What licensing deals affect fexofenadine-pseudoephedrine products?
The current market is not dependent on a major active licensing deal for the ingredients. Fexofenadine and pseudoephedrine are established, widely manufactured compounds. The commercial asset is the Allegra brand and its distribution infrastructure, not proprietary access to either active ingredient.
Sanofi’s consumer-health business has undergone corporate restructuring, including the separation and external investment process involving Opella. Brand ownership and commercialization rights should therefore be evaluated against the applicable Sanofi and Opella corporate structure in each jurisdiction.[6]
Generic manufacturers typically rely on their own regulatory filings and supply arrangements. Contract manufacturing, private-label agreements, and regional distribution deals are commercially relevant, but they do not create a unified global rights structure for the combination.
What generic entry risks exist for Allegra-D?
Generic entry risk is high because:
- The active ingredients are long off-patent.
- The product is nonprescription.
- Multiple manufacturers have experience with both ingredients.
- Consumers can substitute to Claritin-D, Zyrtec-D, or single-ingredient products.
- Retailers have strong incentives to promote private-label alternatives.
The principal constraint is not legal entry. It is operational execution. A generic competitor must maintain compliant pseudoephedrine distribution, satisfy extended-release specifications, manage pharmacy-counter inventory, and achieve sufficient retail placement.
Generic launch scenarios include:
| Scenario |
Likely market result |
| Additional low-price generic entrants |
Faster branded share erosion |
| Retailer private-label expansion |
Lower average selling prices |
| Strong allergy season |
Volume growth across brands, with generic capture |
| Tighter pseudoephedrine rules |
Lower category convenience and possible volume reduction |
| Removal of oral phenylephrine |
Potential shift toward pseudoephedrine products |
| Brand marketing investment |
Temporary stabilization of premium share |
What patent litigation and settlement agreements affect the market?
No active patent litigation is central to the commercial outlook for the mature fexofenadine-pseudoephedrine category. The key market disputes are more likely to involve trademark use, labeling, advertising claims, product equivalence, or regulatory compliance than Paragraph IV litigation.
Paragraph IV challenges are not a material current risk-management issue for the original Allegra-D franchise because the core exclusivity period has expired. A Paragraph IV case would be more relevant to a newly patented reformulation, delivery technology, or combination product than to the established fexofenadine-pseudoephedrine products.
Settlement agreements are also unlikely to determine market timing. Generic entry is governed primarily by regulatory compliance, product availability, retailer acceptance, and pseudoephedrine controls.
How does Allegra-D compare with Claritin-D and Zyrtec-D?
| Factor |
Allegra-D |
Claritin-D |
Zyrtec-D |
| Antihistamine |
Fexofenadine |
Loratadine |
Cetirizine |
| Decongestant |
Pseudoephedrine |
Pseudoephedrine |
Pseudoephedrine |
| Core consumer position |
Nonsedating allergy relief with congestion control |
Established allergy brand with congestion control |
Strong allergy efficacy perception with congestion control |
| Generic pressure |
High |
High |
High |
| Pharmacy-counter requirement |
Yes |
Yes |
Yes |
| Main commercial advantage |
Fexofenadine brand and nonsedating profile |
Brand familiarity and broad household awareness |
Strong consumer recognition in allergy care |
| Main weakness |
Restricted access and generic pricing |
Mature brand competition |
Potential consumer concern about drowsiness |
The products compete primarily on perceived symptom relief, duration, consumer familiarity, and price. Clinical differentiation is limited because all contain the same decongestant class and established second-generation antihistamines.
What is the geographic coverage of fexofenadine-pseudoephedrine products?
Fexofenadine is marketed globally under different brand names and generic labels. Pseudoephedrine availability varies sharply by country because of diversion concerns and local drug-control policies.
The United States remains commercially important because it permits nonprescription pseudoephedrine sales under behind-the-counter controls. In other markets, pseudoephedrine may be prescription-only, subject to stricter pharmacy controls, or excluded from common allergy combinations. This limits the global scalability of the exact U.S. Allegra-D model.
International growth therefore depends more on fexofenadine-only products than on the fixed-dose pseudoephedrine combination. Local regulation, language-specific labeling, reimbursement practices, and pharmacy distribution determine market access.
Key Takeaways
- Fexofenadine and pseudoephedrine are mature, off-patent OTC ingredients.
- Allegra-D is the principal branded fexofenadine-pseudoephedrine franchise in the United States.
- The product has no meaningful core patent exclusivity remaining.
- Generic and store-brand competition creates sustained price pressure.
- Pseudoephedrine purchase controls are the main distribution constraint.
- Fexofenadine-only products have a broader and more stable demand base than Allegra-D.
- Product-level Allegra-D revenue is not separately disclosed by Sanofi or Opella.
- Financial performance depends on seasonal allergy demand, brand pricing, retail placement, and generic substitution.
- FDA action on oral phenylephrine could redirect some decongestant demand toward pseudoephedrine products.
- The commercial value of the franchise lies in brand equity and distribution rather than patent protection.
FAQs
Is fexofenadine-pseudoephedrine still protected by patents?
The core active ingredients and established combination are no longer protected by meaningful composition or market exclusivity. Any residual protection would be limited to specific formulations, manufacturing methods, packaging, or trademarks.
Can a generic manufacturer sell Allegra-D without a prescription?
Generic fexofenadine-pseudoephedrine products may be sold OTC if they satisfy applicable FDA requirements. Because they contain pseudoephedrine, they must follow behind-the-counter sales and transaction-control requirements.
Does Allegra-D have biosimilar competition?
No. Allegra-D is a small-molecule drug combination, not a biologic. The relevant competitors are generic and branded-generic products, not biosimilars.
Which ingredient contributes more to long-term revenue stability?
Fexofenadine generally contributes the broader revenue base because it is sold as a standalone antihistamine for allergic rhinitis and urticaria. Pseudoephedrine increases product utility but narrows access and adds regulatory friction.
Could FDA action on oral phenylephrine increase Allegra-D sales?
It could redirect some demand toward pseudoephedrine-based products if oral phenylephrine products lose OTC status or retail availability. The effect would be limited by behind-the-counter purchase requirements and consumer substitution to nonoral or antihistamine-only products.
References
- U.S. Food and Drug Administration. (n.d.). Allegra-D 12 hour: Fexofenadine hydrochloride and pseudoephedrine hydrochloride drug facts label.
- U.S. Food and Drug Administration. (n.d.). Allegra-D 24 hour: Fexofenadine hydrochloride and pseudoephedrine hydrochloride drug facts label.
- U.S. Congress. (2005). Combat Methamphetamine Epidemic Act of 2005, Pub. L. No. 109-177, Title VII.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). FDA proposes ending use of oral phenylephrine as OTC monograph drug ingredient.
- Sanofi. (2024). Universal registration document and annual financial report 2023.
